What Archon Biosciences does

Archon Biosciences is a preclinical-stage biotechnology company developing the Antibody Cage (AbC) platform, a computationally designed biologic class that integrates the binding affinity and specificity of conventional antibodies with AI-generated protein nanostructures never previously found in nature. The AbC architecture provides geometric control over antibody orientation, binding-domain valency, size, shape, and rigidity, enabling precise biodistribution and target engagement on cells and allowing the platform to be tuned for agonism, antagonism, or preferential biodistribution across indications. The technology was invented in David Baker's lab at the University of Washington's Institute for Protein Design — the work recognized by the 2024 Nobel Prize in Chemistry — and was licensed to Archon by UW.

The company was co-founded in 2023 by James Lazarovits, Ph.D. (CEO) and George Ueda, Ph.D. (CTO), both former Translational Investigators at the IPD, and operates from Seattle, WA. It is staffed with 11-50 employees and is supported by CBO Craig Halder (ex-Adaptive Biotechnologies, Novartis, Amgen) and Head of Research Jon Graves (ex-IFM Therapeutics, TCR2, Tesaro). Initial R&D was funded by more than $7 million in grants from IPD's Translational Program, the Washington Research Foundation, NIH, the Department of Defense, and WE-REACH.

Archon's business model centers on pharmaceutical partnering rather than in-house product commercialization. Revenue, when it materializes, is expected to derive from licensing of the AbC platform, co-development agreements, and milestone payments tied to preclinical, clinical, and commercial advancement with pharma partners (inquiries directed to [email protected]). The company emerged from stealth in October 2024 alongside a $20 million seed round led by Madrona Ventures, with participation from DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments, and Cornucopian Capital. The company has no commercial products, no pricing, and no disclosed revenue.

Name

Archon Biosciences

Legal name

Archon Biosciences, Inc.

Website

https://archon.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Archon Biosciences is a Seattle-based preclinical biotech developing the computationally designed Antibody Cage (AbC) protein therapeutic platform and licensing it to pharmaceutical partners for challenging drug targets.

Ownership category

akta.pro rank

Product category

Biologics / Therapeutic Protein Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Computational protein design
• Antibody therapeutics
• Biologics platform
• Protein engineering
• Antibody cages

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing and Partnership Deals: As a preclinical biotech platform company, Archon is expected to generate revenue through licensing its AbC technology to pharmaceutical partners, co-development agreements, and potential milestone payments tied to preclinical, clinical, and commercial development. The company has indicated partnering inquiries can be directed to [email protected], suggesting an active business development strategy.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Archon Biosciences develops the Antibody Cage (AbC) platform, a novel class of biologics that combines conventional antibodies with AI-generated protein nanostructures. The platform enables geometric engineering of antibody orientation, valency, size, shape, and rigidity to produce tunable therapeutics for challenging drug targets, and is being advanced through pharmaceutical partnerships, licensing, and co-development agreements.

Product overview

Archon Biosciences develops the Antibody Cage (AbC) platform — a unified technology for computationally designing geometrically tunable protein therapeutics. AbCs integrate the binding affinity and specificity of conventional antibodies with AI-designed protein structures to create novel self-assembling nanostructures with differentiated distribution, engagement and function. The AbC platform enables precise control over molecular geometry to unlock therapeutic targets that other modalities cannot reach.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Cage (AbC) Platform A preclinical-stage biologics platform that combines conventional antibodies with computationally designed protein nanostructures to produce geometrically tunable Antibody Cages (AbCs). The platform delivers precise control over antibody orientation, binding domain valency, size, shape, and rigidity, enabling tunable biodistribution and differentiated target engagement for pharmaceutical and biotechnology partners.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Institute for Protein Design (IPD)coreStrategic or Co-development PartnerArchon's AbC technology was invented at the IPD at University of Washington under David Baker's direction. Co-founders Lazarovits and Ueda were former Translational Investigators at IPD. The technology was licensed from UW.
• University of WashingtoncoreStrategic or Co-development PartnerThe AbC technology was developed at UW's Institute for Protein Design and licensed to Archon. Initial grants totaling over $7 million from IPD's Translational Program, NIH, DoD, and WE-REACH supported early development.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Isomorphic Labs: Alphabet subsidiary applying DeepMind's protein structure prediction (AlphaFold) to drug discovery. A well-capitalized incumbent pursuing the same AI protein design space Archon targets, with broader scope across small molecules and biologics.
• AbCellera: Public antibody discovery platform with deep pharma partnerships and a vertically integrated tech stack. Overlaps with Archon in antibody engineering, though AbCellera is more discovery-focused and at much greater scale.

Direct peers

• Absci: AI generative protein design company combining wet-lab high-throughput screening with in-silico design for antibody and protein therapeutics. Directly comparable platform approach and pharma partnering model.
• Generate Biomedicines: Flagship Pioneering-backed generative AI platform for designing novel protein therapeutics across modalities. Directly comparable to Archon's generative protein design approach and pharma partnering model.
• BigHat Biosciences: AI/ML-guided antibody design platform combining wet-lab high-throughput experimentation with computational design. Closely comparable in combining engineered antibodies with generative protein design for therapeutic applications.
• Molecular Partners: Clinical-stage biotech developing designed protein therapeutics (DARPin platform) with modular architecture for tunable function. Comparable in using computationally designed protein scaffolds as alternatives to antibodies.
• Adagene: Clinical-stage antibody engineering platform using AI and dynamic precision engineering to design differentiated antibodies. Comparable in using computational methods to engineer antibody properties for challenging targets.
• Cradle: Generative AI platform for engineering proteins with improved properties, serving biotech and industrial customers. Comparable in its generative protein design methodology and focus on tunable protein engineering.

Emerging players

• Cyrus Biotechnology: Seattle-based protein design software company with roots in the Baker Lab, offering computational protein engineering tools. Comparable as a Baker Lab spinout applying computational protein design to therapeutics, though more software-focused.
• Menten AI: Early-stage AI protein design company focused on de novo enzyme and therapeutic protein design. Comparable in applying generative AI to protein engineering, though at a smaller scale and earlier stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Archon Biosciences